Do analysts recommend ASBP or DYAI?

Dyadic International has a consensus target price of $3.00, suggesting a potential upside of 314.71%. Given Dyadic International's stronger consensus rating and higher possible upside, analysts plainly believe Dyadic International is more favorable than Aspire Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aspire Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Dyadic International 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Do analysts rate ASBP or TPST?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aspire Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is ASBP or TPST more profitable?

Aspire Biopharma's return on equity of 0.00% beat Tempest Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aspire Biopharma N/A N/A -398.04% Tempest Therapeutics N/A -355.61% -121.21%

Does the media refer more to ASBP or TPST?

In the previous week, Tempest Therapeutics had 2 more articles in the media than Aspire Biopharma. MarketBeat recorded 3 mentions for Tempest Therapeutics and 1 mentions for Aspire Biopharma. Tempest Therapeutics' average media sentiment score of 0.71 beat Aspire Biopharma's score of 0.68 indicating that Tempest Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aspire Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tempest Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Is NRSN or ASBP more profitable?

Company Net Margins Return on Equity Return on Assets NeuroSense Therapeutics N/A N/A N/A Aspire Biopharma N/A N/A -398.04%

Do analysts rate AIXC or ASBP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aspire Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is AIXC or ASBP more profitable?

Aspire Biopharma's return on equity of 0.00% beat Qualigen Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Qualigen Therapeutics N/A -771.52% -79.52% Aspire Biopharma N/A N/A -398.04%

Does the media favor AIXC or ASBP?

In the previous week, Qualigen Therapeutics and Qualigen Therapeutics both had 1 articles in the media. Qualigen Therapeutics' average media sentiment score of 0.93 beat Aspire Biopharma's score of 0.68 indicating that Qualigen Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qualigen Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aspire Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate ASBP or VTGN?

VistaGen Therapeutics has a consensus price target of $0.95, indicating a potential upside of 65.05%. Given VistaGen Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe VistaGen Therapeutics is more favorable than Aspire Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aspire Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 VistaGen Therapeutics 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80

Is ASBP or VTGN more profitable?

Aspire Biopharma's return on equity of 0.00% beat VistaGen Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aspire Biopharma N/A N/A -398.04% VistaGen Therapeutics N/A -109.72% -89.62%

Does the media refer more to ASBP or VTGN?

In the previous week, Aspire Biopharma and Aspire Biopharma both had 1 articles in the media. VistaGen Therapeutics' average media sentiment score of 0.94 beat Aspire Biopharma's score of 0.68 indicating that VistaGen Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aspire Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive VistaGen Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Aspire Biopharma (ASBP) Competitors

$6.05 +0.21 (+3.60%)

Closing price 04:00 PM Eastern

Extended Trading

$6.00 -0.05 (-0.91%)

As of 04:28 PM Eastern

Compare

ASBP vs. DYAI, TPST, NRSN, AIXC, and VTGN

Should you buy Aspire Biopharma stock or one of its competitors? MarketBeat compares Aspire Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aspire Biopharma include Dyadic International (DYAI), Tempest Therapeutics (TPST), NeuroSense Therapeutics (NRSN), Qualigen Therapeutics (AIXC), and VistaGen Therapeutics (VTGN). These companies are all part of the "pharmaceutical products" industry.

How does Aspire Biopharma compare to Dyadic International?

Aspire Biopharma (NASDAQ:ASBP) and Dyadic International (NASDAQ:DYAI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, dividends and earnings.

Dyadic International has higher revenue and earnings than Aspire Biopharma. Dyadic International is trading at a lower price-to-earnings ratio than Aspire Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aspire Biopharma	$10K	786.50	-$24.48M	-$116.67	N/A
Dyadic International	$3.09M	8.53	-$7.36M	-$0.23	N/A

Aspire Biopharma has a beta of 0.17, meaning that its stock price is 83% less volatile than the broader market. Comparatively, Dyadic International has a beta of 1.17, meaning that its stock price is 17% more volatile than the broader market.

19.2% of Aspire Biopharma shares are held by institutional investors. Comparatively, 28.0% of Dyadic International shares are held by institutional investors. 5.8% of Aspire Biopharma shares are held by insiders. Comparatively, 20.9% of Dyadic International shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Aspire Biopharma had 1 more articles in the media than Dyadic International. MarketBeat recorded 1 mentions for Aspire Biopharma and 0 mentions for Dyadic International. Dyadic International's average media sentiment score of 0.94 beat Aspire Biopharma's score of 0.68 indicating that Dyadic International is being referred to more favorably in the news media.

Company	Overall Sentiment
Aspire Biopharma	Positive
Dyadic International	Positive

Dyadic International has a consensus target price of $3.00, suggesting a potential upside of 314.71%. Given Dyadic International's stronger consensus rating and higher possible upside, analysts plainly believe Dyadic International is more favorable than Aspire Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aspire Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Aspire Biopharma has a net margin of 0.00% compared to Dyadic International's net margin of -192.40%. Aspire Biopharma's return on equity of 0.00% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aspire Biopharma	N/A	N/A	-398.04%
Dyadic International	-192.40%	-1,005.45%	-77.64%

Summary

Dyadic International beats Aspire Biopharma on 11 of the 16 factors compared between the two stocks.

How does Aspire Biopharma compare to Tempest Therapeutics?

Aspire Biopharma (NASDAQ:ASBP) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.

19.2% of Aspire Biopharma shares are held by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are held by institutional investors. 5.8% of Aspire Biopharma shares are held by insiders. Comparatively, 6.3% of Tempest Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Tempest Therapeutics had 2 more articles in the media than Aspire Biopharma. MarketBeat recorded 3 mentions for Tempest Therapeutics and 1 mentions for Aspire Biopharma. Tempest Therapeutics' average media sentiment score of 0.71 beat Aspire Biopharma's score of 0.68 indicating that Tempest Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aspire Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tempest Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Aspire Biopharma's return on equity of 0.00% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aspire Biopharma	N/A	N/A	-398.04%
Tempest Therapeutics	N/A	-355.61%	-121.21%

Aspire Biopharma has higher revenue and earnings than Tempest Therapeutics. Tempest Therapeutics is trading at a lower price-to-earnings ratio than Aspire Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aspire Biopharma	$10K	786.50	-$24.48M	-$116.67	N/A
Tempest Therapeutics	N/A	N/A	-$26.26M	-$6.01	N/A

Aspire Biopharma has a beta of 0.17, indicating that its stock price is 83% less volatile than the broader market. Comparatively, Tempest Therapeutics has a beta of -1.85, indicating that its stock price is 285% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aspire Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

Tempest Therapeutics beats Aspire Biopharma on 7 of the 12 factors compared between the two stocks.

How does Aspire Biopharma compare to NeuroSense Therapeutics?

NeuroSense Therapeutics (NASDAQ:NRSN) and Aspire Biopharma (NASDAQ:ASBP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and media sentiment.

NeuroSense Therapeutics currently has a consensus price target of $8.50, suggesting a potential upside of 989.60%. Given NeuroSense Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe NeuroSense Therapeutics is more favorable than Aspire Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroSense Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Aspire Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

1.0% of NeuroSense Therapeutics shares are held by institutional investors. Comparatively, 19.2% of Aspire Biopharma shares are held by institutional investors. 27.4% of NeuroSense Therapeutics shares are held by company insiders. Comparatively, 5.8% of Aspire Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

NeuroSense Therapeutics has a beta of 1.56, meaning that its stock price is 56% more volatile than the broader market. Comparatively, Aspire Biopharma has a beta of 0.17, meaning that its stock price is 83% less volatile than the broader market.

In the previous week, Aspire Biopharma had 1 more articles in the media than NeuroSense Therapeutics. MarketBeat recorded 1 mentions for Aspire Biopharma and 0 mentions for NeuroSense Therapeutics. NeuroSense Therapeutics' average media sentiment score of 1.87 beat Aspire Biopharma's score of 0.68 indicating that NeuroSense Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
NeuroSense Therapeutics	Very Positive
Aspire Biopharma	Positive

Company	Net Margins	Return on Equity	Return on Assets
NeuroSense Therapeutics	N/A	N/A	N/A
Aspire Biopharma	N/A	N/A	-398.04%

NeuroSense Therapeutics has higher earnings, but lower revenue than Aspire Biopharma. NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than Aspire Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroSense Therapeutics	N/A	N/A	-$11.12M	-$0.54	N/A
Aspire Biopharma	$10K	786.50	-$24.48M	-$116.67	N/A

Summary

NeuroSense Therapeutics beats Aspire Biopharma on 10 of the 14 factors compared between the two stocks.

How does Aspire Biopharma compare to Qualigen Therapeutics?

Qualigen Therapeutics (NASDAQ:AIXC) and Aspire Biopharma (NASDAQ:ASBP) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation and profitability.

In the previous week, Qualigen Therapeutics and Qualigen Therapeutics both had 1 articles in the media. Qualigen Therapeutics' average media sentiment score of 0.93 beat Aspire Biopharma's score of 0.68 indicating that Qualigen Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qualigen Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aspire Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aspire Biopharma's return on equity of 0.00% beat Qualigen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qualigen Therapeutics	N/A	-771.52%	-79.52%
Aspire Biopharma	N/A	N/A	-398.04%

Qualigen Therapeutics has higher earnings, but lower revenue than Aspire Biopharma. Qualigen Therapeutics is trading at a lower price-to-earnings ratio than Aspire Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qualigen Therapeutics	N/A	N/A	-$16.97M	-$6.47	N/A
Aspire Biopharma	$10K	786.50	-$24.48M	-$116.67	N/A

Qualigen Therapeutics has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market. Comparatively, Aspire Biopharma has a beta of 0.17, suggesting that its stock price is 83% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aspire Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

3.2% of Qualigen Therapeutics shares are held by institutional investors. Comparatively, 19.2% of Aspire Biopharma shares are held by institutional investors. 1.2% of Qualigen Therapeutics shares are held by company insiders. Comparatively, 5.8% of Aspire Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Qualigen Therapeutics and Aspire Biopharma tied by winning 5 of the 10 factors compared between the two stocks.

How does Aspire Biopharma compare to VistaGen Therapeutics?

Aspire Biopharma (NASDAQ:ASBP) and VistaGen Therapeutics (NASDAQ:VTGN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and media sentiment.

In the previous week, Aspire Biopharma and Aspire Biopharma both had 1 articles in the media. VistaGen Therapeutics' average media sentiment score of 0.94 beat Aspire Biopharma's score of 0.68 indicating that VistaGen Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aspire Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
VistaGen Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

19.2% of Aspire Biopharma shares are owned by institutional investors. Comparatively, 78.4% of VistaGen Therapeutics shares are owned by institutional investors. 5.8% of Aspire Biopharma shares are owned by company insiders. Comparatively, 2.9% of VistaGen Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Aspire Biopharma has higher earnings, but lower revenue than VistaGen Therapeutics. VistaGen Therapeutics is trading at a lower price-to-earnings ratio than Aspire Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aspire Biopharma	$10K	786.50	-$24.48M	-$116.67	N/A
VistaGen Therapeutics	$490K	46.54	-$51.42M	-$1.89	N/A

Aspire Biopharma's return on equity of 0.00% beat VistaGen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aspire Biopharma	N/A	N/A	-398.04%
VistaGen Therapeutics	N/A	-109.72%	-89.62%

Aspire Biopharma has a beta of 0.17, indicating that its share price is 83% less volatile than the broader market. Comparatively, VistaGen Therapeutics has a beta of 0.31, indicating that its share price is 69% less volatile than the broader market.

VistaGen Therapeutics has a consensus price target of $0.95, indicating a potential upside of 65.05%. Given VistaGen Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe VistaGen Therapeutics is more favorable than Aspire Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aspire Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
VistaGen Therapeutics	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Summary

VistaGen Therapeutics beats Aspire Biopharma on 8 of the 13 factors compared between the two stocks.

Get Aspire Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ASBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ASBP vs. The Competition

Export

Metric	Aspire Biopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.87M	$3.35B	$6.44B	$12.47B
Dividend Yield	N/A	2.37%	2.69%	5.22%
P/E Ratio	-0.05	18.72	23.87	24.40
Price / Sales	786.50	320.32	521.86	117.01
Price / Cash	N/A	110.40	41.27	57.13
Price / Book	-0.11	6.80	9.99	6.73
Net Income	-$24.48M	$24.09M	$3.56B	$337.03M
7 Day Performance	9.40%	-2.48%	-0.87%	0.11%
1 Month Performance	N/A	N/A	N/A	-1.70%
1 Year Performance	-98.71%	48.95%	28.77%	34.24%

Aspire Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ASBP Aspire Biopharma	0.5966 of 5 stars	$6.05 +3.6%	N/A	-98.7%	$7.87M	$10K	N/A	N/A
DYAI Dyadic International	2.222 of 5 stars	$0.76 +2.6%	$3.00 +295.2%	-30.2%	$27.66M	$3.09M	N/A	7	High Trading Volume
TPST Tempest Therapeutics	1.89 of 5 stars	$1.86 +2.8%	N/A	-81.4%	$27.54M	N/A	N/A	20	Gap Down
NRSN NeuroSense Therapeutics	3.5465 of 5 stars	$0.82 +6.1%	$8.50 +936.6%	-55.1%	$26.70M	N/A	N/A	10
AIXC Qualigen Therapeutics	0.5126 of 5 stars	$1.29 -6.5%	N/A	N/A	$26.10M	N/A	N/A	50

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ASBP) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aspire Biopharma (ASBP) Competitors

ASBP vs. DYAI, TPST, NRSN, AIXC, and VTGN

How does Aspire Biopharma compare to Dyadic International?

Summary

How does Aspire Biopharma compare to Tempest Therapeutics?

Summary

How does Aspire Biopharma compare to NeuroSense Therapeutics?

Summary

How does Aspire Biopharma compare to Qualigen Therapeutics?

Summary

How does Aspire Biopharma compare to VistaGen Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASBP vs. The Competition

Aspire Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aspire Biopharma (ASBP) Competitors

ASBP vs. DYAI, TPST, NRSN, AIXC, and VTGN

How does Aspire Biopharma compare to Dyadic International?

Which has preferable valuation & earnings, ASBP or DYAI?

Which has more risk and volatility, ASBP or DYAI?

Do insiders and institutionals have more ownership in ASBP or DYAI?

Does the media refer more to ASBP or DYAI?

Do analysts recommend ASBP or DYAI?

Is ASBP or DYAI more profitable?

Summary

How does Aspire Biopharma compare to Tempest Therapeutics?

Do institutionals and insiders have more ownership in ASBP or TPST?

Does the media refer more to ASBP or TPST?

Is ASBP or TPST more profitable?

Which has stronger valuation & earnings, ASBP or TPST?

Which has more volatility and risk, ASBP or TPST?

Do analysts rate ASBP or TPST?

Summary

How does Aspire Biopharma compare to NeuroSense Therapeutics?

Do analysts prefer NRSN or ASBP?

Do institutionals & insiders have more ownership in NRSN or ASBP?

Which has more risk and volatility, NRSN or ASBP?

Does the media refer more to NRSN or ASBP?

Is NRSN or ASBP more profitable?

Which has higher earnings & valuation, NRSN or ASBP?

Summary

How does Aspire Biopharma compare to Qualigen Therapeutics?

Does the media favor AIXC or ASBP?

Is AIXC or ASBP more profitable?

Which has better earnings and valuation, AIXC or ASBP?

Which has more risk and volatility, AIXC or ASBP?

Do analysts rate AIXC or ASBP?

Do institutionals and insiders believe in AIXC or ASBP?

Summary

How does Aspire Biopharma compare to VistaGen Therapeutics?

Does the media refer more to ASBP or VTGN?

Do institutionals and insiders believe in ASBP or VTGN?

Which has preferable earnings and valuation, ASBP or VTGN?

Is ASBP or VTGN more profitable?

Which has more risk and volatility, ASBP or VTGN?

Do analysts rate ASBP or VTGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASBP vs. The Competition

Aspire Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools